Globus Medical Inc - Class A risk profile
40 Elevated one input has moved against it
Measured 21 October 2026 from GMED's filed statements. Recomputed nightly.
40 (Elevated), driven by Concentration at 78, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 47 | Elevated | Volatile | One-year price volatility — 48.9% |
| Operating pressure | 26 | Normal | Easing | Operating-margin drift — -6.0 percentage points |
| Cash conversion | 23 | Normal | Worsening | Cash conversion — 1.40x |
| Leverage and coverage | 2 | Contained | Easing | Current ratio — 4.26x |
| Competitive position | 37 | Normal | Stable | R&D-intensity gap against peers — -11.4 percentage points |
| Concentration | 78 | Stretched | Stable | Geographic concentration — 6,490 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Globus Medical Inc - Class A